<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02429193</url>
  </required_header>
  <id_info>
    <org_study_id>BARRIER-P</org_study_id>
    <nct_id>NCT02429193</nct_id>
  </id_info>
  <brief_title>Biomarkers of Androgen Response and Resistance In Evolution During a Rising PSA</brief_title>
  <acronym>BARRIER-P</acronym>
  <official_title>An Open-label Phase 2 Multi-center Study of Enzalutamide and Abiraterone and Biomarkers of Androgen Response and Resistance During Rising PSA: BARRIER-P Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Health Network, Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Health Network, Toronto</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label phase 2 multi-center study of abiraterone and enzalutamide in men with
      castration-resistant prostate cancer. Sixteen patients will be enrolled over 18 months.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in expression of androgen receptor abnormalities (e.g. ARV7, AR mutations) following abiraterone/enzalutamide treatment</measure>
    <time_frame>18 months</time_frame>
    <description>The change in protein expression of androgen receptor (AR7) splice variant and AR / AR pathway mutations as a mechanism of resistance to abiraterone/enzalutamide is evaluated by measuring the difference in a quantitative immunohistochemical biomarker between assays performed before and after treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of PSA increase</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to PSA progression</measure>
    <time_frame>18 months</time_frame>
    <description>PSA progression is defined as a ≥ 25% increase and an absolute increase of ≥ 2 µg/L (2 ng/mL) above the nadir.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of participants with adverse events from the administration of abiraterone, enzalutamide, and prednisone to men with early stage prostate cancer.</measure>
    <time_frame>18 months</time_frame>
    <description>The number of participants experiencing adverse events will be evaluated to determine the safety of abiraterone, enzalutamide, and prednisone treatment in men with early stage prostate cancer, .</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Castration-resistant Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Abiraterone / enzalutamide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Abiraterone + prednisone; Enzalutamide</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abiraterone + prednisone</intervention_name>
    <description>Abiraterone acetate (1000 mg/day p.o.) + prednisone (5 mg b.i.d., p.o.)</description>
    <arm_group_label>Abiraterone / enzalutamide</arm_group_label>
    <other_name>abiraterone acetate</other_name>
    <other_name>Zytiga</other_name>
    <other_name>prednisone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enzalutamide</intervention_name>
    <description>Enzalutamide (160 mg/day p.o.)</description>
    <arm_group_label>Abiraterone / enzalutamide</arm_group_label>
    <other_name>Xtandi</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with histologically or cytologically confirmed prostate cancer

          -  Able to read and understand the consent form, either alone or with the aid of a
             translator

          -  Surgically or medically castrated, with testosterone levels of &lt; 50 ng/dL (&lt; 2.0
             nmol/L). If the patient is being treated with luteinizing hormone-releasing hormone
             (LHRH) agonists (patients who have not undergone orchiectomy), they must remain on
             continuous androgen suppression therapy throughout the study

          -  Patients receiving bone-targeted therapies must be on stable doses for at least 4
             weeks prior to enrollment

          -  Historical frozen/paraffin-embedded diagnostic tissue specimens are available for
             analysis (i.e. radical prostatectomy or biopsy tissue)

          -  Documented metastatic disease by positive bone scan or metastatic lesions (on CT or
             MRI) that can be biopsied with an anticipated minimum of 4 cores, as assessed by the
             local radiologist

          -  prostate cancer progression at study entry defined as one or more of the following
             criteria: i. Rising PSA: minimum of two rising PSA levels with an interval of ≥ 1 week
             between each determination ii. Soft tissue disease progression, as defined by RECIST
             1.1 iii. Bone disease progression, as defined by PCWG2 with two or more new lesions on
             bone scan

          -  PSA value at screening visit ≥ 2 µg/L (2 ng/mL)

          -  ECOG performance status 0-2

          -  Adequate organ and BM function, as defined by the following criteria:

             i. absolute neutrophil count ≥1,500/µL ii. platelets ≥100,000/µL iii. total bilirubin
             ≤1.5 × institutional upper limit of normal (ULN) iv. AST(SGOT) or ALT(SGPT) ≤2.5 ×
             institutional ULN v. creatinine ≤1.5 × institutional ULN or below

          -  Serum albumin ≥ 3.0 g/dL

          -  Serum potassium ≥ 3.5 mmol/L

          -  Haemoglobin ≥ 10.0 g/dL, independent of transfusion

          -  Asymptomatic or mildly symptomatic from prostate cancer

          -  Life expectancy of &gt; 6 months

          -  Able to swallow study drugs

          -  Patients who have partners of childbearing potential must be willing to use a method
             of birth control with adequate barrier protection as determined to be acceptable by
             the principal investigator and sponsor during the study and for 13 weeks after last
             study drug administration

        Exclusion Criteria:

          -  Patients with known hypersensitivity or allergy to abiraterone acetate, enzalutamide
             or any of their excipients.

          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, congestive heart failure (NYHA Class 3 or greater), cirrhosis with a
             Child-Pugh level of B or greater or evidence of cardiac dysfunction, unstable angina
             pectoris, cardiac arrhythmia, myocardial infarction within 6 months, hypotension
             (defined by systolic blood pressure &lt; 86 mmHg at Screening visit), hypertension
             (defined by systolic blood pressure &gt; 170 mmHg or diastolic blood pressure &gt; 105 mmHg
             at Screening visit), bradycardia (defined by &lt; 50 beats per minute on ECG performed at
             screening), active peptic ulcer disease, clinically significant gastrointestinal
             conditions (e.g. Crohns disease, ulcerative colitis), any seizure disorder or
             psychiatric illness, and social situations that would limit compliance with study
             requirements

          -  Active invasive malignancy at any other site excluding squamous cell or basal cell
             carcinomas of the skin

          -  Known or suspected brain metastasis or leptomeningeal disease

          -  Radiotherapy within the past 4 weeks, except for low dose palliative radiation to bone
             of ≤5 fractions

          -  Treatment with 5-α reductase inhibitors (finasteride, dutasteride), androgen receptor
             antagonists (bicalutamide, nilutamide, flutamide), estrogens, cyproterone within 4
             weeks of Day 1 visit
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anthony Joshua, MD,MBBS,PhD,FRACP</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Health Network, Toronto</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>British Columbia Cancer Agency, Vancouver Cancer Centre</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4E6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 25, 2015</study_first_submitted>
  <study_first_submitted_qc>April 23, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 29, 2015</study_first_posted>
  <last_update_submitted>October 24, 2017</last_update_submitted>
  <last_update_submitted_qc>October 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Abiraterone Acetate</mesh_term>
    <mesh_term>Androgens</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

